Navigation Links
Amgen’s Fourth Quarter 2010 Adjusted Earnings Per Share Increased 11 Percent to $1.17; Full Year 2010 Adjusted Earnings Per Share Increased 6 Percent to $5.21
Date:1/24/2011

oward managed care and health care cost containment as well as U.S. legislation affecting pharmaceutical pricing and reimbursement.  Government and others’ regulations and reimbursement policies may affect the development, usage and pricing of our products.  Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities.  We or others could identify safety, side effects or manufacturing problems with our products after they are on the market.  Our business may be impacted by government investigations, litigation and product liability claims.  Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors.  We depend on third parties for a significant portion of our manufacturing capacity for the supply of certain of our current and future products and limits on supply may constrain sales of certain of our current products and product candidate development.  In addition, we compete with other companies with respect to some of our marketed products as well as for the discovery and development of new products.  Discovery or identification of new product candidates cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate will be successful and become a commercial product.  Further, some raw materials, medical devices and component parts for our products are supplied by sole third-party suppliers.  

About AmgenAmgen discovers, develops, manufactures, and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science’s promise by bringing safe, effective medicines from lab to manufacturing p
'/>"/>

SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related medicine technology :

1. Amgen’s Third Quarter 2010 Revenue Unchanged at $3.8 Billion Versus Prior Year
2. Neurocrine Biosciences Reports Fourth Quarter and Year-End 2007 Results
3. Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financial Results
4. PLC Systems Reports Fourth Quarter 2007 Results
5. Memory Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Financial Results
6. Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights
7. GeoVax Labs, Inc. Reports Fourth Quarter and Year-End 2007 Financial Results
8. Novavax Reports Fourth Quarter and 2007 Year-End Financial Results
9. Catalyst Pharmaceutical Partners Reports Fourth Quarter and Year-End 2007 Financial Results
10. Halozyme Therapeutics Announces Roche Begins Phase 1 Clinical Trial and Selects Fourth Exclusive Biologic Target
11. Human Genome Sciences Announces Fourth-Quarter and Full-Year 2008 Financial Results and Key Developments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... N.J. , July 30, 2015 Eisai ... in the United States , European ... FDA, EMA and MHLW, respectively) for eribulin, for the ... who have received prior chemotherapy for advanced or metastatic ... on data from a pivotal global Phase 3 clinical ...
(Date:7/30/2015)... July 30, 2015 Future Market ... titled, "Continuous Glucose Monitoring Systems Market: Global Industry Analysis ... report, the global continuous glucose monitoring systems market was ... expected to reach US$ 788.4 Mn by 2020, registering ... to 2020. Global continuous glucose monitoring systems ...
(Date:7/30/2015)... N.J. , July 30, 2015  Medimetriks ... completed the second Phase III clinical study for ... for impetigo.  Medimetriks owns the exclusive U.S. rights ... global trial, conducted at 44 centers with an ... pediatric patients aged 2 months and older with ...
Breaking Medicine Technology:Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 2Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 3Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 4Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 5Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 2Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 3Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 4Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 2Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 3
... , , Part ... SPRING, Md., Nov. 19 The U.S. Food and ... called the International Internet Week of Action (IIWA), intended ... http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO ) , During the effort, the FDA,s ...
... NEWS, Va., Nov. 19 Breast-Specific Gamma Imaging/Molecular Breast ... highly esteemed organizations for the fight against breast cancer: ... College of Surgeons. Both societies published articles supporting the ... early detection of breast cancer. , "These endorsements reinforce ...
Cached Medicine Technology:UPDATE: FDA Issues 22 Warning Letters to Web site Operators 2Esteemed Endorsements Recognize Promising Future of Breast-Specific Gamma Imaging (BSGI) 2Esteemed Endorsements Recognize Promising Future of Breast-Specific Gamma Imaging (BSGI) 3
(Date:7/30/2015)... ... 2015 , ... The Mesothelioma Applied Research Foundation (Meso Foundation) ... of 2015’. The bill was introduced in Congress yesterday by Representatives John Katko ... Joe Kennedy (D-MA), and Leonard Lance (R-NJ). The purpose of the bill is ...
(Date:7/30/2015)... ... ... On July 23rd Clay Today Online reported the state of ... prison system, which has amassed largely enough throughout the years. Florida is the third ... Obama’s recent reduction of non violent drug offender’s prison sentences, Florida is beginning to ...
(Date:7/30/2015)... ... July 30, 2015 , ... ... Acting Administrator Chuck Rosenberg’s announcement of the reinstitution of National Prescription Drug Take-Back ... 26, 2015 from 10:00 AM to 2:00 PM local time. On the 26th, ...
(Date:7/30/2015)... ... , ... Bird B Gone, the leader in bird control products for commercial, ... pest birds from the AC units and ventilation systems on hospital roofs. Bird droppings ... West Nile virus. When these droppings dry, the fine powder can be carried into ...
(Date:7/30/2015)... ... July 30, 2015 , ... Summer is the dry eye season, ... that a particularly long, dry and hot 2015 summer season and the dry eye ... advocate Sharon Kleyne will discuss the 2015 summer season and identify the primary dry ...
Breaking Medicine News(10 mins):Health News:Bill to Create Patient Registry for Deadly Cancer Introduced in Congress 2Health News:Florida Questions Its Spending on Punitive Incarceration in Light of Exorbitant Costs for Non Violent Offenders 2Health News:Florida Questions Its Spending on Punitive Incarceration in Light of Exorbitant Costs for Non Violent Offenders 3Health News:AAPCC Supports National Prescription Drug Take-Back Day 2Health News:AAPCC Supports National Prescription Drug Take-Back Day 3Health News:Bird B Gone’s New Bird Hazing System Keeps Disease-Carrying Bird Droppings Out of Hospitals 2Health News:Fresh Water Advocate Sharon Kleyne Warns to Be Extra Cautious About Dry Eye “Hot Spot” Cities In Hot Dry Summer of 2015 2Health News:Fresh Water Advocate Sharon Kleyne Warns to Be Extra Cautious About Dry Eye “Hot Spot” Cities In Hot Dry Summer of 2015 3
... the nation,s leading,supplier of replacement medical repair parts for ... companies in Ohio by the Case Western,Weatherhead School of ... growth rate exceeding 1000% and has won the award ... clearly one of our region,s most prestigious,honors," said PartsSource ...
... could yield targeted treatments for leukemia, bone marrow transplants ... of all human blood cells has been identified by ... to new treatments for blood cancers and other blood ... progenitor, is the initial offspring of a blood-forming stem ...
... Inc.,(NYSE: BMR ) today announced that its board ... $0.31 per share of common stock. The,dividend is equivalent ... BioMed also announced that its board of directors ... company,s 7.375% Series A Cumulative,Redeemable Preferred Stock for the ...
... WASHINGTON, Dec. 12 Speaker Nancy Pelosi,Majority Leader Steny ... Rahm Emanuel held a news conference late this afternoon ... news conference, President,Bush vetoed the bill. Below are the ... that later today that the President,will veto the SCHIP ...
... experts say recall shouldn,t be health threat , , WEDNESDAY, ... 1.2 million doses of a common childhood vaccine due ... vaccine does not pose a health threat, U.S. health ... recalled two lots of the Haemophilus influenzae ...
... A new school curriculum,that counters abuse of prescription ... a press conference today in Washington, D.C. The,curriculum ... as presentations,for parents. This curriculum was created by ... and expertise of law enforcement,officials; the Pharmaceutical Research ...
Cached Medicine News:Health News:BioMed Realty Trust Declares Fourth Quarter 2007 Common Stock and Preferred Stock Dividends 2Health News:Pelosi on Bush Veto of SCHIP: 'Democrats Will Not Rest Until 10 Million Children Have Access to Health Care' 2Health News:Common Infant Vaccine Recalled 2Health News:Common Infant Vaccine Recalled 3Health News:New School Curriculum Addresses Rx and OTC Drug Abuse 2Health News:New School Curriculum Addresses Rx and OTC Drug Abuse 3Health News:New School Curriculum Addresses Rx and OTC Drug Abuse 4
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: